Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBT: 2017-2024

Historic EBT for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$36.2 million.

  • Kiniksa Pharmaceuticals International's EBT rose 477.13% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 153.31%. This contributed to the annual value of -$36.2 million for FY2024, which is 60.33% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its EBT stood at -$36.2 million for FY2024, which was up 60.33% from -$91.1 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's EBT's 5-year high stood at $95.1 million during FY2022, with a 5-year trough of -$164.3 million in FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's EBT had a median value of -$36.2 million in 2024 and averaged -$10.7 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EBT spiked by 157.88% in 2022, and later plummeted by 195.84% in 2023.
  • Kiniksa Pharmaceuticals International's EBT (Yearly) stood at -$162.0 million in 2020, then fell by 1.42% to -$164.3 million in 2021, then spiked by 157.88% to $95.1 million in 2022, then tumbled by 195.84% to -$91.1 million in 2023, then spiked by 60.33% to -$36.2 million in 2024.